alexa Cardiomyopathy | Switzerland| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Cardiomyopathy

  • Cardiomyopathy

    Patho physiology: Cardiomyopathy refers to diseases of the heart muscle. These diseases have many causes, signs and symptoms, and treatments.In cardiomyopathy, the heart muscle becomes enlarged, thick, or rigid. In rare cases, the muscle tissue in the heart is replaced with scar tissue.As cardiomyopathy worsens, the heart becomes weaker. It's less able to pump blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or irregular heartbeats called arrhythmias. In turn, heart failure can cause fluid to build up in the lungs, ankles, feet, legs, or abdomen.The weakening of the heart also can cause other complications, such as heart valve problems.

  • Cardiomyopathy

    Treatment: People who have cardiomyopathy but no signs or symptoms may not need treatment. Sometimes, dilated cardiomyopathy that comes on suddenly may go away on its own. For other people who have cardiomyopathy, treatment is needed. Treatment depends on the type of cardiomyopathy you have, the severity of your symptoms and complications, and your age and overall health. Treatments may include: Heart-healthy lifestyle changes, Medicines, Nonsurgical procedure, Surgery and implanted devices. The main goals of treating cardiomyopathy include: • Controlling signs and symptoms so that you can live as normally as possible • Managing any conditions that cause or contribute to the disease • Reducing complications and the risk of sudden cardiac arrest • Stopping the disease from getting worse

  • Cardiomyopathy

    Research: Prevalence and Disease Outcome: because recognition of inherited disease is often limited by practice patterns which are in turn heavily influenced by the urgent demands of caring for sick patients, an important proportion of inherited disease is misdiagnosed. As an example, we discovered that nearly 25% of patients undergoing heart transplant for end stage cardiomyopathy have inherited disease, whereas current recognition of inherited disease in this population is limited to 4% of patients. This research was presented at the International Society of Heart and Lung Transplant in Prague (2012).

  • Cardiomyopathy

    Statistics: Among 16,202 non-elective admissions for CAPP in patients aged 18–74years, 2685 had AUD. Patients admitted with CAPP and AUD were predominantly men with a higher prevalence of tobacco or drug use disorders and higher Charlson comorbidity index. Patients with CAPP and AUD had notably higher in-hospital mortality (50.8%; CI 95%: 44.3–54.3%), prolonged length of stay (2.3days; CI 95%: 2.0–2.7days) and increased costs (1869.2€; CI 95%: 1498.6–2239.8€). Age-adjusted mortality rates per 100000 inhabitants who died from PTB decreased from 4.1 to 2 between 2000 and 2009. Men (67.7%) presented higher mortality than women (32.3%). Individuals failing to complete elementary education presented a higher risk of dying from PTB (RR 1.08 [95% CI: 1.05–1.12]). The socioeconomic region and the entities with the strongest association were regions 1, 5, Chiapas and Baja California. Region 1 in 2007 presented RR 7.34 (95% CI: 5.32–10.13), and region 5 in 2009 had RR 10.08 (95% CI: 6.83–14.88). Speaker PPTs

Speaker PPTs

High Impact List of Articles

Conference Proceedings

Top